AI in Drug Safety: How New Technology Helps the FDA Spot Problems Earlier and What That Means for Patients
- Vanessa Muller
- Jan 1
- 5 min read
By Vanessa Muller, PharmD
Most people don’t think about the technology behind medication safety. You pick up a prescription, read the instructions, and trust that if something important changes, your doctor will hear about it.
But the amount of safety information that experts handle today is far greater than it used to be. Every year, the U.S. Food and Drug Administration (FDA) reviews millions of safety reports, research findings, electronic health-record patterns, and global alerts. It’s more information than any team of people could read manually.
To keep up with this growing volume, the FDA and other regulators have begun using artificial intelligence (AI) tools to help sort through data and identify important patterns sooner. AI does not replace human experts or make decisions on its own, but it can help safety reviewers spot signals earlier, leading to clearer warnings, faster label updates, and better protection for patients.
This article explains how AI is being used, why it matters, and what patients can expect as these systems continue to develop.
Why AI Is Needed in Medication Safety
The goal of drug safety has always been the same: catch potential problems early and communicate them clearly. But since 2020, the type and amount of information health agencies review has expanded rapidly:
More digital reports from hospitals and pharmacies
More real-world data from electronic health records
More patient-reported events
More complex medications and drug combinations
Larger datasets from manufacturers
AI helps with the volume of information, not the judgement. It functions like a powerful organizing tool grouping similar reports, highlighting unexpected changes, and summarizing large collections of information so experts can focus on what matters most.
How the FDA Uses AI in Plain Language
Here are the main ways the FDA uses AI to support post-market drug safety:
1. Sorting and organizing the high volume of reports:
AI helps the FDA group together similar cases, remove duplicate ones, and highlight unusual patterns, anomalies and outliers, in the FDA Adverse Event Reporting System (FAERS).
2. Spotting signals earlier
AI looks for unexpected increases in certain side effects, especially rare ones, and alerts human reviewers to investigate.
3. Scanning research automatically
Instead of manually searching thousands of publications, AI helps identify new safety findings in medical literature, studies, case reports, and global alerts.
4. Supporting label reviews
AI can summarize evidence or compare drug labels across similar medications, giving reviewers a starting point before they write the final language themselves.
5. Drafting early summaries
Generative AI sometimes helps prepare early versions of internal summaries but it is still up to FDA experts to produce the final versions.
AI assists a large and complex information management process. It does NOT approve drugs, make decisions, or replace human subject matter expertise or judgment.
How the Pharmaceutical Industry Uses AI
Manufacturers face a similar information overload challenge. Just as the FDA, they have been able to successfully leverage AI in processing vast amounts of unstructured and semi-structured data. Examples include:
Extracting information from patient phone calls and hospital reports
Checking for mistakes or missing information such as patient demographics, clinical data, drug dosages, side effects, regulatory documents and safety reports ensures all required facts and data are complete and accurate.
Organizing materials for regulatory submissions
Creating early drafts of safety summaries
These tools are distilling understanding and meaning from vast amounts of unorganized and noisy data. Just like at the FDA, all AI assisted work must be reviewed, standardized, and validated by trained safety professionals. They can’t replace human review or expertise.
The Benefits and Risks Patients Should Know About
Faster and more consistent safety alerts
Earlier identification of rare side effects
Quicker changes to drug labels
Better alignment of warnings across medications in the same class
These improvements help clinicians stay informed and support safer prescribing.
Potential risks:
AI tools are only as good as the data they receive. Potential challenges include:
Bias: If certain groups (children, older adults, underserved communities) aren’t well-represented in data, signals may be harder to detect.
False alarms: Sometimes a cluster of reports can look like a trend when it’s not.
Missed events: Rare reactions may be overlooked if reporting is low.
A simple example:
If one large hospital suddenly reports many cases of the same side effect, misapplied AI may flag it because of the skew in the data, even if it’s not happening anywhere else.
But if small clinics serving marginalized communities don’t submit reports, important events might not show up early because it isn’t in the data.
This is why human oversight remain
Human Guardrails Are A Must
Even as AI tool usage grows, it is very important to recognize its limitations and as such there are several rules that must never change:
AI cannot
Approve safety actions
Decide what goes on a drug label
Assess risk–benefit decisions
Replace human regulatory judgment
These guardrails are built into U.S., European, and Canadian safety frameworks. AI can assist, but only trained reviewers make regulatory decisions. AI actions and decisions must be transparent, monitored, and validated. AI does not have legal accountability, cannot ensure compliance with data privacy regulations or ethical standards.
What Patients Will Notice in the Coming Years
As AI tools continue to support safety efforts, patients may see:
Faster updates. Warnings or label changes appear sooner in news stories, EHR portals, or pharmacy counseling.
More safety messages. Your healthcare team will receive more frequent Drug Safety Communications.
Earlier identification of rare events. Patterns may surface faster, especially when signals appear in large datasets.
Clearer and more consistent language. Warnings across medications within the same class will match more closely.
What Patients Can Do
For patients to get the most benefit from these AI improvements, it’s still important to stay actively involved in their own care. Here are a few ways to do that.
Read messages from your pharmacy or healthcare provider
Patient engagement can maximize the benefits of AI in drug safety monitoring. Ask questions if you see an alert and don’t understand what it means.
Check for updates on medications you use regularly. Use digital tools such as portals or apps which may be part of AI powered safety systems for easier tracking and communication.
Report unexpected side effects, even if they seem minor
Patient reports provide unique insights into side effects and medication experiences that algorithms and professionals may miss
Your voice and your experiences will always remain essential to drug safety.
Conclusion
AI is becoming an important information tool in medication safety, helping experts find patterns faster and communicate risks sooner. But it’s not replacing people, it’s supporting them. The safest system is one where guardrails exist to ensure that AI is used as an effective tool with human expertise driving critical decisions which will ultimately , make sure patients stay informed and protected.
Disclosure
The author is a federal pharmacist writing in a personal capacity. The views expressed are her own.
References
1. FDA CDER. FAERS Modernization and Artificial Intelligence Updates. 2024.
2. FDA Sentinel Initiative. Use of AI and Real-World Evidence in Postmarket Safety. 2024.
3. FDA Office of Emerging Sciences. Artificial Intelligence in Regulatory Review: Public Update. 2024.
4. FDA AI/ML Initiatives in Drug Development and Safety. Public Presentations, 2023–2025.
5. European Medicines Agency. Reflection Paper on the Use of Artificial Intelligence in the Medicinal Product Lifecycle. 2024.
6. Health Canada. Emerging Technologies in Pharmacovigilance: Current Initiatives. 2024.
Assessed and Endorsed by the MedReport Medical Review Board
